Kristin Kaasen Jørgensen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll et al. · JAMA · 2021 · 160 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 122 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen et al. · JAMA · 2021 · 121 citations · Full text

Medicine, Immunology, Pharmacology +17

A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency

Silje F. Jørgensen, Henrik M. Reims, D.S. Frydenlund et al. · The American Journal of Gastroenterology · 2016 · 119 citations

Medicine, Immunology, Pathology +17